Elisabeth A Minthorn
Overview
Explore the profile of Elisabeth A Minthorn including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
14
Citations
700
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Brocks D, Minthorn E, Davies B
J Pharm Pharmacol
. 2024 Jan;
76(3):245-256.
PMID: 38262451
Objective: In pharmacokinetics, the area under the concentration versus time curve (AUC) extrapolated to infinity (AUC0-∞) is the preferred metric but it is not always possible to have a reliable...
2.
Miles T, Hennessy A, Bax B, Brooks G, Brown B, Brown P, et al.
Bioorg Med Chem Lett
. 2016 Apr;
26(10):2464-2469.
PMID: 27055939
During the course of our research on the lead optimisation of the NBTI (Novel Bacterial Type II Topoisomerase Inhibitors) class of antibacterials, we discovered a series of tricyclic compounds that...
3.
Dumble M, Crouthamel M, Zhang S, Schaber M, Levy D, Robell K, et al.
PLoS One
. 2014 Jul;
9(6):e100880.
PMID: 24978597
Tumor cells upregulate many cell signaling pathways, with AKT being one of the key kinases to be activated in a variety of malignancies. GSK2110183 and GSK2141795 are orally bioavailable, potent...
4.
Miles T, Hennessy A, Bax B, Brooks G, Brown B, Brown P, et al.
Bioorg Med Chem Lett
. 2013 Aug;
23(19):5437-41.
PMID: 23968823
During the course of our research to find novel mode of action antibacterials, we discovered a series of hydroxyl tricyclic compounds that showed good potency against Gram-positive and Gram-negative pathogens....
5.
Smith D, Minthorn E, Beerahee M
Clin Pharmacokinet
. 2011 Feb;
50(4):215-27.
PMID: 21348536
Mepolizumab is a fully humanized monoclonal antibody (IgG1/κ) targeting human interleukin-5 (IL-5), a key haematopoietin needed for eosinophil development and function. Mepolizumab blocks human IL-5 from binding to the α-chain...
6.
Gilmartin A, Bleam M, Groy A, Moss K, Minthorn E, Kulkarni S, et al.
Clin Cancer Res
. 2011 Jan;
17(5):989-1000.
PMID: 21245089
Purpose: Despite their preclinical promise, previous MEK inhibitors have shown little benefit for patients. This likely reflects the narrow therapeutic window for MEK inhibitors due to the essential role of...
7.
Lin H, Yamashita D, Xie R, Zeng J, Wang W, Leber J, et al.
Bioorg Med Chem Lett
. 2009 Dec;
20(2):684-8.
PMID: 20006500
The synthesis and evaluation of tetrasubstituted aminopyridines, bearing novel azaindazole hinge binders, as potent AKT inhibitors are described. Compound 14c was identified as a potent AKT inhibitor that demonstrated reduced...
8.
Lin H, Yamashita D, Zeng J, Xie R, Wang W, Nidarmarthy S, et al.
Bioorg Med Chem Lett
. 2009 Dec;
20(2):673-8.
PMID: 20006497
2,3,5-Trisubstituted pyridines have been designed as potent AKT inhibitors that are selective against ROCK1 based on the comparison between AKT and ROCK1 structures. Substitution at the 2-position of the core...
9.
Lin H, Yamashita D, Zeng J, Xie R, Verma S, Luengo J, et al.
Bioorg Med Chem Lett
. 2009 Dec;
20(2):679-83.
PMID: 20005102
A novel series of AKT inhibitors containing 2,3,5-trisubstituted pyridines with novel azaindazoles as hinge binding elements are described. Among these, the 4,7-diazaindazole compound 2c has improved drug-like properties and kinase...
10.
Seefeld M, Rouse M, McNulty K, Sun L, Wang J, Yamashita D, et al.
Bioorg Med Chem Lett
. 2009 Mar;
19(8):2244-8.
PMID: 19285393
A pyrrolopyridinyl thiophene carboxamide 7 was discovered as a tractable starting point for a lead optimization effort in an AKT kinase inhibition program. SAR studies aided by a co-crystal structure...